At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 30, 2026 at 07:00 ET
PDS Biotechnology reported financial results for 2025 and provided a clinical update, including a Phase 3 trial amendment for its lead candidate PDS0101 to incorporate progression-free survival as an interim primary endpoint, which could enable accelerated approval in HPV16-positive head and neck cancer. The company reduced operating expenses and improved net loss compared to 2024, but ended the year with $26.7 million in cash, down from $41.7 million, raising concerns about runway. Early data from a PDS01ADC trial showed promising median PFS of 9.6 months in prostate cancer.
- Net loss for 2025 was $34.5 million ($0.74/share), improved from $37.6 million ($1.03/share) in 2024.
- R&D expenses decreased to $19.0 million from $22.6 million in 2024, driven by lower manufacturing and personnel costs.
- Cash balance declined to $26.7 million as of December 31, 2025, from $41.7 million in 2024, a 36% reduction.
- Amended VERSATILE-003 Phase 3 trial to include PFS as an interim primary endpoint to potentially accelerate approval for PDS0101.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access